TSS
MRKR icon

Two Sigma Securities’s Marker Therapeutics MRKR Stock Holding History

Two Sigma Securities’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,460
Closed -$14.9K – 2127
2026
Q1 		$14.9K Buy
+11,460
New +$18.2K ﹤0.01% 1420
2025
Q4 		– Sell
-47,603
Closed -$42.5K – 1820
2025
Q3 		$42.5K Buy
+47,603
New +$58.8K 0.01% 1010
2023
Q1 		– Sell
-1,873
Closed -$4.98K – 3049
2022
Q4 		$4.98K Buy
+1,873
New +$6.46K ﹤0.01% 2451

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Two Sigma Securities's MRKR Position: Q2 2026 in Review

Two Sigma Securities sold out of Marker Therapeutics (MRKR) in Q2 2026, closing a stake of 11,460 shares — an estimated $14.9K sold.

Two Sigma Securities first reported a position in MRKR in Q4 2022 and held it in 3 quarters. The position peaked at $42.5K in Q3 2025. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Two Sigma Securities reported no remaining Marker Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 11,460 Marker Therapeutics shares in Q2 2026, an estimated $14.9K.
  • Two Sigma Securities first reported a position in Marker Therapeutics in Q4 2022 and held it in 3 quarters.
  • Two Sigma Securities's Marker Therapeutics position peaked at $42.5K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.